According to the report "Multiple Myeloma Therapeutics Market" published by Market Data Forecast, the global market is projected to reach USD 9.1 Billion by 2021, at a CAGR of 4.8% from 2016 to 2021.

For full report refer at http://www.marketdataforecast.com/market-reports/global-multiple-myeloma-therapeutics-market-858/

Multiple myeloma remains comparatively rare, it is a deceptive disease and patients typically deplete treatment alternatives. Myeloma and MGUS are twice as common in blacks paralleled with whites and marginally more common in males than females. The Multiple Myeloma (MM) market is presently dominated by Velcade and Revlimid, and the market is set to experience considerable growth between 2016 and 2021.

Free sample for the report is available at http://www.marketdataforecast.com/market-reports/global-multiple-myeloma-therapeutics-market-858/request-sample

Expanding indications of existing drugs, emergence of new and promising drugs, increasing incidence of multiple myeloma and increasing use of drugs already on the market are fuelling growth of the market. Factors such as varied therapeutic areas, rising investment in research and development for new therapies, increasing demand and extensive off-label use of IG are some of the foremost factors contributing to the growth of the multiple myeloma therapeutics market.

Request Customization at http://www.marketdataforecast.com/market-reports/global-multiple-myeloma-therapeutics-market-858/customize-report

Segmented as:

 1)By Treatment Type:
   a)Chemotherapy
      -Anthracycline antibiotic
      -Melphalan (Alkeran)
      -Liposomal doxorubicin (Doxil)
      -Alkylating agent
      -Doxorubicin (Adriamycin)
      -Cyclophosphamide (Neosar)
      -Vincristine (Oncovin)
      -Carmustine (BiCNU) 
    b)Targeted therapy
      -Proteasome inhibitor    
      -Bortezomib (Velcade)
      -Carfilzomib (Kyprolis)

2)By Drug Type
    a)Corticosteroids 
       -Dexamethasone (Decadron)
       -Prednisone (Deltasone/Orasone)
    b)Immunomodulatory agents
       -Thalidomide (Thalomid)
       -Lenalidomide  (Revlimid)
       -Arsenic trioxide  (Trisenox)
       -Plerixafor  (Mozobil)

3)By Geography:
   a)North America 
   b)Europe
   c)Asia-Pacific
   d)Latin America
   e)Middle-East and Africa

Inquire more about the report at http://www.marketdataforecast.com/market-reports/global-multiple-myeloma-therapeutics-market-858/inquire

Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.

Buy now at https://www.marketdataforecast.com/cart/buy-now/global-multiple-myeloma-therapeutics-market-858

About Market Data Forecast:

Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organisation that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.

Contact:

Market Data Forecast, Inc.

Jubilee Gardens,

Hyderabad, India.

+1-888-702-9626 (U.S. TOLL FREE)

contact@marketdataforecast.com